查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403382

神经内分泌肿瘤治疗市场的全球市场预测（~2030）：治疗方法、疾病状态、给药途径、部位分析、最终用户和区域进行分析

Neuroendocrine Tumor Treatment Market Forecasts to 2030 - Global Analysis By Service, Animal Model, Model Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年全球神经内分泌肿瘤治疗市场规模为25.872亿美元，预计预测期内复合年增长率为15.7%，到2030年将达到71.807亿美元。

神经内分泌肿瘤治疗包括一系列旨在治疗神经内分泌肿瘤（NET）的医疗干预措施，神经内分泌肿瘤是由神经内分泌细胞产生的一组不同的罕见肿瘤。这些肿瘤可发生在许多器官中，但最常发生在胰臟和消化器官系统。

根据国家转化科学推进中心-遗传和罕见疾病资讯中心2021年11月更新的资料，美国约有3,000至30,000人患有类癌，这种肿瘤通常发生在胃肠道或胃肠道。在肺部。

扩大神经内分泌肿瘤治疗

患者数量的不断增加促使製药和生物技术公司投入资金进行研发，透过早期诊断和适当的干预措施来改善患者的治疗结果。诊断技术的改进、意识的提高、生活方式的改变以及透过分子分析进行的精准医疗等多种因素正在实现个体化治疗策略并推动该市场的规模。

昂贵的治疗费用

由于处方药、医疗程序、住院和后续观察护理的费用，患者可能难以负担昂贵的治疗费用，特别是如果他们负担不起或没有足够的保险。治疗神经内分泌肿瘤的高昂费用可能会使卫生系统难以分配足够的资源，从而可能限制获得这些基本治疗方法并使这些基本治疗方法变得更加难以负担。此外，保险覆盖范围的差异和高额共付额进一步阻碍患者获得最佳护理。

研发进度

分子分析已成为 NET 研究的一个重要方面，可以识别与这些肿瘤相关的特定生物标记和基因突变。这些发现导致了生长抑制素类似物、mTOR 抑制剂和胜肽受体放射性核素疗法 (PRRT) 等创新治疗方法的引入。此外，不断的科学发现有助于更深入地了解分子机制和遗传因素，最终改善患者预后并扩大可用治疗方法的范围，从而增加市场潜力。我们正在促进成长。

缺乏意识

神经内分泌肿瘤 (NET) 相对罕见，并且可能出现多种症状，因此难以检测。许多医学相关人员对这些肿瘤知之甚少，这可能导致延误诊断或误诊。此外，缺乏对 NET 的了解可能会导致对症状的误解和寻求医疗护理的延迟。这种认知的缺乏延伸到了更广泛的医学界，并可能导致 NET 病例的管理不理想。

COVID-19 的影响

神经内分泌肿瘤治疗市场受到 COVID-19大流行的负面影响。医疗机构的关闭和能力有限导致神经内分泌肿瘤的检测和治疗延迟，影响了患者的治疗结果。由于创新药物的临床试验受到限制，资源和注意力都集中在应对这场流行病上，卫生服务的利用放缓。此外，对免疫抑制和医疗系统财政限制的担忧也影响了开始和维持治疗的意愿，逐渐缩小了市场规模。

预计化疗领域在预测期内将是最大的

化疗部分估计占最大份额。当手术和其他治疗方法无效时，通常是在 NET 的晚期或转移阶段，通常会考虑化疗。化疗可以帮助控制症状、减缓肿瘤生长并改善患者的生活质量，但治疗并不总是有效。此外，正在研究有针对性的个人个体化化疗方案，以减少神经内分泌肿瘤患者的副作用并改善治疗结果，从而推动这一领域的扩张。

预计胰臟神经内分泌肿瘤部分在预测期内复合年增长率最高

预计胰臟神经内分泌肿瘤部分在预测期内复合年增长率最高。这些肿瘤起源于胰臟中的内分泌细胞，其独特的特征值得考虑专门治疗。 pNET 的治疗方法包括考虑肿瘤恶性、分期和功能等因素的多学科策略。此外，进行性或转移性 pNET 的治疗选择包括生长抑制素类似物，可控制荷尔蒙相关症状并抑制促进肿瘤生长的途径，从而推动该部分的生长。

比最大的地区

由于 PET- 电脑断层扫描和分子分析等先进诊断工具增强了神经内分泌肿瘤的早期检测和表征，预计亚太地区将在估计期间占据最大的市场占有率。标靶治疗和免疫疗法越来越受到关注，提供了更有效和个体化的治疗选择。此外，医疗保健相关人员、政府机构和製药公司之间的合作对于解决这些差异和加强整体神经内分泌肿瘤治疗至关重要，这正在推动该地区的增长。Masu。

复合年增长率最高的地区：

由于政府医疗保健政策和保险覆盖范围显着影响患者获得治疗的机会，预计北美在预测期内将呈现最高的复合年增长率。由于该地区严格的监管以及医疗保健和研究方面的大规模公共和私人投资，礼来公司、诺华公司、和记黄埔医药有限公司和辉瑞公司等大公司正在良好的环境中发展。美国食品药物管理局(FDA) 等监管机构在核准药品和治疗设备以确保安全性和有效性方面发挥核心作用，这推动了该地区的扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球神经内分泌肿瘤治疗市场：依治疗方法分类

  • 化疗
  • 标靶治疗
  • 生长抑制素类似物
  • 免疫疗法
  • 其他治疗方法

第六章全球神经内分泌肿瘤治疗市场：依疾病状况

  • 胰臟神经内分泌肿瘤
  • 肺神经内分泌肿瘤
  • 胃肠道神经内分泌肿瘤
  • 其他医疗状况

第七章全球神经内分泌肿瘤治疗市场：依给药途径

  • 胃肠外的
  • 口服

第八章全球神经内分泌肿瘤治疗市场：按地点分析

  • 冒号
  • 肺
  • 小肠
  • 胰臟
  • 其他站点分析

第九章全球神经内分泌肿瘤治疗市场：依最终用户分类

  • 医院药房
  • 网路药房
  • 零售药房
  • 其他最终用户

第十章全球神经内分泌肿瘤治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Novartis AG
  • Exelixis, Inc.
  • Boehringer Ingelheim International GmbH
  • Tarveda Therapeutics
  • Dauntless Pharmaceuticals
  • Hutchison MediPharma Limited
  • AVEO Oncology
  • Pfizer Inc.
  • Ipsen Pharma
  • Progenics Pharmaceuticals, Inc.
  • Eli Lilly & Company
  • Lantheus Holdings, Inc.
  • Jubilant Life Sciences Ltd.
Product Code: SMRC24607

According to Stratistics MRC, the Global Neuroendocrine Tumor Treatment Market is accounted for $2,587.2 million in 2023 and is expected to reach $7,180.7 million by 2030 growing at a CAGR of 15.7% during the forecast period. Neuroendocrine tumor treatment encompasses a range of medical interventions aimed at managing neuroendocrine tumors (NETs), a diverse group of rare neoplasms that arise from neuroendocrine cells. These tumors can develop in a number of organs, although they most frequently affect the pancreas and digestive system.

According to the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs.

Market Dynamics:

Driver:

Expansion of neuroendocrine tumor treatments

The growing number of patients has encouraged pharmaceutical and biotechnology businesses to spend money on research and development for better patient outcomes and appropriate interventions resulting from early diagnosis. Several factors including improved diagnostic techniques, greater awareness, and changes in lifestyle, precision medicine, guided by molecular profiling, allows for personalized therapeutic strategies, which are driving this market size.

Restraint:

High treatment costs

Patients may find it difficult to receive high-cost treatments, especially if they have limited financial resources or insufficient insurance, due to the expense of prescription drugs, medical procedures, hospital stays, and follow-up care. The high expense of treating neuroendocrine tumors may make it difficult for healthcare systems to devote enough funding, which could restrict the accessibility and affordability of these essential treatments. Furthermore, insurance coverage gaps and high out-of-pocket expenses further impede patient access to optimal treatment.

Opportunity:

Advancements in research developments

Molecular profiling has emerged as a key aspect of NET research, enabling the identification of specific biomarkers and genetic mutations associated with these tumors. These discoveries have led to the introduction of innovative treatment options such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). Moreover, the ongoing scientific discoveries contribute to a deeper understanding of molecular mechanisms and genetic factors, ultimately enhancing patient outcomes and expanding the range of available treatments, thereby driving market growth.

Threat:

Lack of awareness

Neuroendocrine tumors (NETs) are difficult to detect since they are comparatively uncommon and present with a variety of symptoms. These tumors may not be well known to many medical professionals, which could cause delayed or incorrect diagnoses. Additionally, lack of knowledge on NETs, causes them to incorrectly interpret symptoms and delay seeking medical attention. This lack of awareness also extends to the broader medical community, potentially leading to suboptimal management of NET cases.

COVID-19 Impact

The market for neuroendocrine tumor treatments was adversely affected by the COVID-19 pandemic. Patient outcomes were impacted by delayed neuroendocrine tumor detection and treatment as a result of lockdowns and restricted capacity in healthcare facilities. Clinical trials for innovative medicines were restricted, and the availability of healthcare services was stretched due to the reallocation of resources and attention toward addressing the pandemic. Furthermore, concerns about immunosuppression and financial limitations on healthcare systems also affected the willingness to start or maintain therapy, gradually hindering the market size.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is typically considered in cases where surgery and other treatments are less effective, often in the advanced or metastatic stages of NETs. Chemotherapy can help control symptoms, reduce tumor growth, and enhance the patient's quality of life, but treatment is not always curative. Moreover, targeted and individualized chemotherapy regimens are being investigated in order to reduce side effects and improve treatment outcomes for people with neuroendocrine tumors, which is boosting this segment's expansion.

The pancreatic neuroendocrine tumor segment is expected to have the highest CAGR during the forecast period

The pancreatic neuroendocrine tumor segment is anticipated to have the highest CAGR during the forecast period. These tumors arise from the endocrine cells of the pancreas, and their distinct characteristics necessitate specialized treatment considerations. Treatment approaches for pNETs involve a multidisciplinary strategy, considering factors such as tumor grade, stage, and functionality. Additionally, for advanced or metastatic pNETs, therapeutic options include somatostatin analogs, which help control hormone-related symptoms and inhibit pathways promoting tumor growth, which are driving this segment's growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to advanced diagnostic tools, such as PET-CT scans and molecular profiling that have enhanced the early detection and characterization of neuroendocrine tumors. Targeted therapies and immunotherapies have gained prominence, offering more effective and personalized treatment options. Furthermore, collaborative efforts among healthcare stakeholders, government bodies, and pharmaceutical companies are crucial to addressing these disparities and enhancing the overall NET treatment, which is driving this region's growth.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to government healthcare policies and insurance coverage that significantly influence patient access to these treatments. Key players such as Eli Lilly & Company, Novartis AG, Hutchison MediPharma Limited, and Pfizer Inc. are developing in a favorable environment due to the region's strict regulations and large public and private investments in healthcare and research. Regulatory bodies like the FDA (Food and Drug Administration) play a central role in drug and treatment device approvals, ensuring safety and efficacy, which are propelling this region's expansion.

Key players in the market:

Some of the key players in the Neuroendocrine Tumor Treatment Market include Novartis AG, Exelixis, Inc., Boehringer Ingelheim International GmbH, Tarveda Therapeutics, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer Inc., Ipsen Pharma, Progenics Pharmaceuticals, Inc., Eli Lilly & Company, Lantheus Holdings, Inc. and Jubilant Life Sciences Ltd.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In August 2023, Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines.

Therapies Covered:

  • Chemotherapy
  • Targeted Therapy
  • Somatostatin Analogues
  • Immunotherapy
  • Other Therapies

Disease Indications Covered:

  • Pancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor
  • Gastrointestinal Neuroendocrine Tumor
  • Other Disease Indications

Route of Administrations Covered:

  • Parenteral
  • Oral

Site Analysis Covered:

  • Colon
  • Lungs
  • Small Intestine
  • Pancreas
  • Other Site Analysis

End Users Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuroendocrine Tumor Treatment Market, By Therapy

  • 5.1 Introduction
  • 5.2 Chemotherapy
  • 5.3 Targeted Therapy
  • 5.4 Somatostatin Analogues
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Neuroendocrine Tumor Treatment Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Pancreatic Neuroendocrine Tumor
  • 6.3 Lung Neuroendocrine Tumor
  • 6.4 Gastrointestinal Neuroendocrine Tumor
  • 6.5 Other Disease Indications

7 Global Neuroendocrine Tumor Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Neuroendocrine Tumor Treatment Market, By Site Analysis

  • 8.1 Introduction
  • 8.2 Colon
  • 8.3 Lungs
  • 8.4 Small Intestine
  • 8.5 Pancreas
  • 8.6 Other Site Analysis

9 Global Neuroendocrine Tumor Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy
  • 9.5 Other End Users

10 Global Neuroendocrine Tumor Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novartis AG
  • 12.2 Exelixis, Inc.
  • 12.3 Boehringer Ingelheim International GmbH
  • 12.4 Tarveda Therapeutics
  • 12.5 Dauntless Pharmaceuticals
  • 12.6 Hutchison MediPharma Limited
  • 12.7 AVEO Oncology
  • 12.8 Pfizer Inc.
  • 12.9 Ipsen Pharma
  • 12.10 Progenics Pharmaceuticals, Inc.
  • 12.11 Eli Lilly & Company
  • 12.12 Lantheus Holdings, Inc.
  • 12.13 Jubilant Life Sciences Ltd.

List of Tables

  • Table 1 Global Neuroendocrine Tumor Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 3 Global Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 4 Global Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 5 Global Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 6 Global Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 8 Global Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 9 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 10 Global Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 11 Global Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 12 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 13 Global Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 15 Global Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 17 Global Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 18 Global Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 19 Global Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 20 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 21 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 22 Global Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 24 Global Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 25 Global Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 29 North America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 30 North America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 31 North America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 32 North America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 33 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 34 North America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 35 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 36 North America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 37 North America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 38 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 39 North America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 40 North America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 41 North America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 42 North America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 43 North America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 44 North America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 45 North America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 46 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 47 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 48 North America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 50 North America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 51 North America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 North America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 55 Europe Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 56 Europe Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 57 Europe Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 58 Europe Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 59 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 60 Europe Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 61 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 62 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 63 Europe Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 64 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 65 Europe Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 66 Europe Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 67 Europe Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 68 Europe Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 69 Europe Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 70 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 71 Europe Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 72 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 73 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 74 Europe Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 76 Europe Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 77 Europe Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 78 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 81 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 82 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 83 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 84 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 85 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 86 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 87 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 88 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 89 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 90 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 91 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 92 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 93 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 94 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 95 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 96 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 97 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 98 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 99 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 100 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 102 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 103 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 104 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 107 South America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 108 South America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 109 South America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 110 South America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 111 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 112 South America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 113 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 114 South America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 115 South America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 116 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 117 South America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 118 South America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 119 South America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 120 South America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 121 South America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 122 South America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 123 South America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 124 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 125 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 126 South America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 128 South America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 129 South America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 130 South America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 134 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 135 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 136 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 137 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 138 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 139 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 140 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 141 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 142 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 143 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 144 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 145 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 146 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 147 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 148 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 149 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 150 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 151 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 152 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 154 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 155 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 156 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)